Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Taiho Pharmaceutical Co., Ltd.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proved adenocarcinoma
Unresectable and recurrent colorectal cancer
Age20 ≤ at enrollment
Performance status 0 or 1 (ECOG)
No prior treatment (ex. radiation therapy, chemotherapy, hormonal therapy) to advanced disease. Patients who received adjuvant chemotherapy more than 180 days before enrollment can be allowed but those who received S-1 containing treatment shall be excluded
Adequate hematologic, hepatic and renal functions
At least one measurable lesion by RECIST criteria
You may not be if
Serious drug hypersensitivity
Pregnant or nursing
Bleeding from gastrointestinal tract
Diarrhea
Simultaneously active double cancer
Serious illness or medical condition
Brain metastasis
Clareo Health | Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer
